NSE filing, NSE: MANKIND. Summary written from the filing by ALFA Finder's alert engine.
Mankind Pharma Ltd: key numbers
- Share price
- ₹2,502.70
- Market cap
- ₹1,03,373 Cr
- Revenue (annual)
- ₹14,278 Cr
- Net profit (annual)
- ₹1,913 Cr
- P/E (TTM)
- 46.1×Sector 48.7×
- Promoter holding
- 72.62%-0.01% QoQ
- FII holding
- 9.37%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Mankind Pharma Ltd
All →Mankind Pharma Credit Rating
CRISIL reaffirmed Mankind Pharma's AA+ rating on Rs.2,500 Crore of NCDs and withdrew ratings on Rs.2,500 Crore NCDs and Rs.1,500 Crore commercial paper. The rating action is dated October 29, 2026.
Mankind Pharma Earnings Call Transcript: Key Takeaways
Mankind Pharma delivered robust Q2 growth driven by chronic therapies and B-Spec specialty expansion. Strong operating leverage and margin expansion offset muted consumer health performance.
- Call
- Guides 20% growth
Mankind Pharma Investor Presentation: Key Takeaways
Q2 FY27 revenue ₹4,338 Cr (+17.3% YoY), EBITDA ₹1,175 Cr (27.1% margin), PAT ₹716 Cr (+37.7%). Domestic ex-CH +15.9%, exports +32.7%, CH +1.2%.
Mankind Pharma Results Update
Mankind Pharma reported Q2 FY27 revenue of ₹4,338 Cr, up 17% YoY, and PAT of ₹716 Cr, up 38%. EBITDA margin improved 210 bps to 27.1%.
Mankind Pharma Acquisition
Mankind Pharma's board approved amalgamation of two wholly owned subsidiaries into the parent and a step-down subsidiary merger into MCPPL. Schemes require NCLT and shareholder approvals.
Mankind Pharma Q2 FY27 Results: Net Profit ₹716.1 Cr, Up 37.7% YoY
Mankind Pharma Ltd reported revenue from operations of ₹4,338 Cr (+17.3% YoY) and net profit of ₹716.1 Cr (+37.7% YoY) for Q2 FY27.
- Key figure
- Net profit ₹716.1 Cr · +37.7% YoY
Other annual general meeting announcements
All →Dhunseri Investments Annual General Meeting
Dhunseri Investments declared the result of a postal ballot approving the appointment of Mrs. Aditi Kanodia as Non-Executive Independent Director, passed on 29 October 2026. The voting outcome and scrutinizer report were filed with the exchanges.
Ashapuri Gold Ornament Annual General Meeting
Ashapuri Gold Ornament held its 18th AGM on 30 October 2026, transacting eight resolutions including auditor appointment and remuneration revisions. No transaction value is disclosed.
Wealth First Portfolio Managers Annual General Meeting
EGM notice seeks approval for preferential allotment and a ₹60 Crore RPT cap with Lakshya Asset Management. Meeting scheduled for November 21, 2026 via video conference.
Thyrocare Technologies Annual General Meeting
Thyrocare Technologies reported postal ballot voting results approving the purchase of land and building from, and divestment of its entire shareholding in, Nueclear Healthcare Limited.
Uravi Defence and Technology Annual General Meeting
Uravi Defence seeks postal ballot approval for up to Rs.6 Crore unsecured loans from directors. Remote e-voting runs October 30 to November 28, 2026.
Accord Synergy Annual General Meeting
Accord Synergy's postal ballot seeks approval for Mr. Betulla Khan's ₹5 lakh monthly remuneration as Business Development Head. E-voting closes November 30, 2026.
- Execution
- 1 year, 17 September 2026 to 16 September 2027